Passage Bio Statistics
Share Statistics
Passage Bio has 61.77M shares outstanding. The number of shares has increased by 12.67% in one year.
| Shares Outstanding | 61.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 51.33M |
| Failed to Deliver (FTD) Shares | 829 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 1.64M, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 1.64M |
| Short % of Shares Out | 2.66% |
| Short % of Float | 3.34% |
| Short Ratio (days to cover) | 6.61 |
Valuation Ratios
The PE ratio is -0.54 and the forward PE ratio is -1.34.
| PE Ratio | -0.54 |
| Forward PE | -1.34 |
| PS Ratio | 0 |
| Forward PS | 24 |
| PB Ratio | 0.5 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | n/a |
Enterprise Valuation
Passage Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.22, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.22 |
| Quick Ratio | 7.22 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 2.94 |
| Cash Flow / Debt | -23.2 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.92% and return on capital (ROIC) is -78.78%.
| Return on Equity (ROE) | -0.92% |
| Return on Assets (ROA) | -0.68% |
| Return on Capital (ROIC) | -78.78% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.76M |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -1.44% in the last 52 weeks. The beta is 1.2, so Passage Bio 's price volatility has been higher than the market average.
| Beta | 1.2 |
| 52-Week Price Change | -1.44% |
| 50-Day Moving Average | 0.65 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 550.45K |
Income Statement
In the last 12 months, Passage Bio had revenue of $0 and earned -$102.06M in profits. Earnings per share was $-1.86.
| Revenue | 0 |
| Gross Profit | -3.72M |
| Operating Income | -108.39M |
| Net Income | -102.06M |
| EBITDA | -98.34M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.86 |
Balance Sheet
The company has $21.71M in cash and $26.29M in debt, giving a net cash position of -$4.58M.
| Cash & Cash Equivalents | 21.71M |
| Total Debt | 26.29M |
| Net Cash | -4.58M |
| Retained Earnings | -594.47M |
| Total Assets | 111.75M |
| Working Capital | 70.27M |
Cash Flow
In the last 12 months, operating cash flow was -$78.26M and capital expenditures -$146.00K, giving a free cash flow of -$78.41M.
| Operating Cash Flow | -78.26M |
| Capital Expenditures | -146.00K |
| Free Cash Flow | -78.41M |
| FCF Per Share | -1.43 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PASG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -251.35% |
| FCF Yield | -171.78% |
Analyst Forecast
The average price target for PASG is $7, which is 845.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 845.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -8.76 |
| Piotroski F-Score | 2 |